within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX59_Enasidenib;

model Enasidenib
  extends Pharmacolibrary.Drugs.ATC.L.L01XX59;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XX59</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Enasidenib is an oral, selective inhibitor of isocitrate dehydrogenase 2 (IDH2), used primarily in the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. It is approved by the FDA and is currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients (female and male) with relapsed or refractory AML following oral administration.</p><h4>References</h4><ol><li><p>Stein, EM, et al., &amp; Tallman, MS (2017). Enasidenib in mutant . <i>Blood</i> 130(6) 722–731. DOI:<a href=\"https://doi.org/10.1182/blood-2017-04-779405\">10.1182/blood-2017-04-779405</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28588020/\">https://pubmed.ncbi.nlm.nih.gov/28588020</a></p></li><li><p>Li, Y, et al., &amp; Zhou, S (2018). Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects. <i>Pharmacology research &amp; perspectives</i> 6(6) e00436–None. DOI:<a href=\"https://doi.org/10.1002/prp2.436\">10.1002/prp2.436</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30386625/\">https://pubmed.ncbi.nlm.nih.gov/30386625</a></p></li><li><p>Del Principe, MI, et al., &amp; Venditti, A (2019). An evaluation of enasidenib for the treatment of acute myeloid leukemia. <i>Expert opinion on pharmacotherapy</i> 20(16) 1935–1942. DOI:<a href=\"https://doi.org/10.1080/14656566.2019.1654456\">10.1080/14656566.2019.1654456</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31454277/\">https://pubmed.ncbi.nlm.nih.gov/31454277</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Enasidenib;
